p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling

Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway

(2017) Xia Li et al.   PHARMACOLOGICAL RESEARCH

Effective Killing of Cancer Cells Through ROS-Mediated Mechanisms by AMRI-59 Targeting Peroxiredoxin I

(2016) Yeon Ju Yang et al.   ANTIOXIDANTS & REDOX SIGNALING

ROS Function in Redox Signaling and Oxidative Stress

(2014) Michael Schieber et al.   CURRENT BIOLOGY

Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters

(2014) Jayne Loughery et al.   NUCLEIC ACIDS RESEARCH

Diverse Mechanisms of AKT Pathway Activation in Human Malignancy

(2013) Mitchell Cheung et al.   CURRENT CANCER DRUG TARGETS

Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry

(2013) Y. Zhu et al.   GENES & DEVELOPMENT

Activation of the PI3K/Akt pathway by oxidative stress mediates high glucose-induced increase of adipogenic differentiation in primary rat osteoblasts

(2013) Yu Zhang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers

(2013) Xinyuan Li et al.   Journal of Hematology & Oncology

Management of non-small-cell lung cancer: recent developments

(2013) Martin Reck et al.   LANCET

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

(2012) Tongyuan Li et al.   CELL

Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy

(2011) Subash C. Gupta et al.   ANTIOXIDANTS & REDOX SIGNALING

Phosphorylation of p53 on Ser15 during cell cycle and caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation

(2011) Hong Zhao et al.   CELL CYCLE

Signal transduction by reactive oxygen species

(2011) Toren Finkel   JOURNAL OF CELL BIOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway

(2009) Peixin Dong et al.   Molecular Cancer

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

(2009) T John et al.   ONCOGENE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt

(2008) X Yang et al.   BRITISH JOURNAL OF CANCER

A Novel Antioxidant Function for the Tumor-Suppressor Gene p53 in the Retinal Ganglion Cell

(2008) J. C. O'Connor et al.   INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer

(2008) A. Astanehe et al.   JOURNAL OF CELL SCIENCE